Presently, more than 40 Aptamer-based drug candidates are being investigated across different phases of development for the treatment of a myriad of disease indications.
The aptamers market size is estimated to be worth $451 million in 2024 and is expected to reach $12,782 million by 2035, growing at CAGR of 36% during the forecast period, till 2035.
During our research, we were able to identify over 15 aptamer-based therapeutics developers. aptamer-based therapeutic market is presently dominated by the presence of small companies, followed by very small firms and mid-sized players.
During our research, we observed that majority of the players offer both study design and sample preparation services. Furthermore, aptamer-based therapeutic developers are presently based in North America, followed by those headquartered in Europe and Asia-Pacific. Nearly 50% of the Aptamer-Based Technology Providers are Based in North America; Most of the Technologies are Focused on Drug Discovery and Development Related Applications
The primary purpose of this analysis was to develop a better understanding of the overall potential and capabilities of players involved in this domain. It is worth highlighting that the input data used for this analysis was collated from publicly available sources. Further, at no point should the inferences presented in this section be construed as a recommendation that one company is better than another.
The following approach was adopted to compare various companies that are engaged in this domain:
· As a starting point, we collated information for the service providers engaged in the aptamer domain.
· These companies were then segregated on the basis of company size, namely very small, small, mid-sized, large and very large companies.
· The company competitiveness score was assessed across each region, based on service strength (based on company’s experience and company size), portfolio strength (based on type of service providers), and portfolio diversity (scale of operation, area of application, number of technologies used for analysis and types of analysis offered). Further, the size of the bubble was calculated using the portfolio diversity.
During our research, we were able to identify over 50 aptamer-based technologies. aptamer-based therapeutic market is presently dominated by the presence of small companies, followed by very small firms and mid-sized players.
In Pursuit of Gaining a Competitive Edge, Industry Stakeholders are Actively Innovating and Inventing New Aptamer-Based Technologies that can be Utilized in a Wide Range Application Areas.
The following approach was adopted to compare various technologies that are developed/ underdevelopment in this domain:
· As a starting point, we collated information on the abovementioned parameters for 53 technologies engaged in the aptamer domain.
· These companies were then segregated on the basis of company size, namely very small, small, mid-sized, large and very large companies.
· The technology competitiveness score was assessed across each company size segment, based on service strength (based on company’s experience), portfolio diversity (based on type of aptamer, application area, status of development, types of technology used and technology application).
To cope up with the current and future market demand, players engaged in the domain are actively collaborating with various stakeholders across the globe.
During our research, we came across several partnerships and collaborations that have been inked between various stakeholders engaged in developing / providing aptamer-based therapeutics, technologies and services. Out of all the partnerships, companies are continuously striving R&D agreements emerged as the most popular type of partnership model. The high research activity in this domain can be attributed to the efforts of players to further advance increase the number of candidates in the pipeline. This was followed by instances of product development agreements and merger and acquisitions.
Most of the agreements signed within this domain were instances wherein both the developer and partner were based in Asia-Pacific. Further, in terms of intercontinental agreements, most of the deals were instances wherein a player based in North America entered into a partnership with a company headquartered in Europe.
Thank you for reading our report. Kindly get in touch with us to know more about the report or to receive a customized copy of it. Our team will ensure the report is tailored according to your needs.
To view more details on this report, click on the link
https://www.rootsanalysis.com/reports/aptamers-therapeutics-technologies-and-services-market.html
About Roots Analysis
Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights.
We specialise in analysing areas which have lacked quality research so far or require more focused understanding within the broader industry. All our reports are structured in a way to enable the reader develop a thorough perspective on the given subject. Apart from writing reports on identified areas, we also provide bespoke research / consulting services dedicated to serve our clients in the best possible way.
The research efforts are driven by a global team. The leadership team brings a wealth of experience within the sector. Their collective experience in pharmaceutical / affiliated domains allows us to tackle various areas of research in a structured way. We also regularly leverage our global network of experts who hold senior leadership positions in reputed firms and organisations worldwide.
Contact:
Roots Analysis
Gaurav Chaudhary
+1 (415) 800 3415
+44 (122) 391 1091
Gaurav.chaudhary@rootsanalysis.com
Website: https://www.rootsanalysis.com/